Skip to main content
. Author manuscript; available in PMC: 2011 May 12.
Published in final edited form as: Chem Rev. 2010 May 12;110(5):3196–3211. doi: 10.1021/cr900317f

Figure 3.

Figure 3

Dose-dependent inhibition of 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine (DiI)-labeled (A) and acridine orange-labeled (B–G) DU-145 human prostate carcinoma cell adhesion to the endothelium by synthetic TF antigen-specific P30 peptide but not by control peptide (H). In B–H, numbers at the bottom indicate the concentration of the peptide tested. I and J, maximal inhibitory effect on adhesion of MDA-MB-435 human breast carcinoma (I) and DU-145 human prostate carcinoma (J) cells to the endothelium achievable with anti-TF antigen monoclonal antibody and P-30 peptide; bars, SD. Reprinted with permission from reference number 5 (Figure 2), Copyright 2001 American Association for Cancer Research, Inc.